This site is intended for health professionals only

Dynavax trials hepatitis B vaccine


US biopharmaceutical company Dynavax is planning a phase III trial of its Heplisav adult hepatitis B vaccine in chronic kidney-disease patients.

The new drug is designed to provide increased and rapid protection with fewer doses than current licensed alternatives.

Dynavax has worldwide commercial rights to Heplisav, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 (TLR9) agonist to enhance the immune response.

The company reports that 2,500 people have been vaccinated with Heplisav to date. Data from PHAST clinical trials reportedly show a seroprotection rate of 92%, compared to 75% of subjects receiving 3 doses of a licensed vaccine over six month

Says Dynavax boss Dino Dina: “The success of our scientific approach to resolving the clinical hold on Heplisav allows us to resume development of our hepatitis B vaccine.

“After achieving strong efficacy data in our prior phase 3 pivotal trial, we are fully prepared to initiate the final registration trials for Heplisav.”

Copyright Press Association 2009


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine